In the last trading session, 1.13 million Apellis Pharmaceuticals Inc (NASDAQ:APLS) shares changed hands as the company’s beta touched 0.93. With the company’s per share price at $33.93 changed hands at -$0.21 or -0.62% during last session, the market valuation stood at $4.19B. APLS’s last price was a discount, traded about -117.51% off its 52-week high of $73.80. The share price had its 52-week low at $24.34, which suggests the last value was 28.26% up since then. When we look at Apellis Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 4.67 million shares, with the 3-month average coming to 3.09 million.
Analysts gave the Apellis Pharmaceuticals Inc (APLS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.65. If we narrow down to specifics, the data shows that 0 out of 14 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. Of the remaining, 2 recommended APLS as a Hold, 11 felt it is a Buy and 0 rated the stock as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Apellis Pharmaceuticals Inc (NASDAQ:APLS) trade information
Instantly APLS was in red as seen at the end of in last trading. With action 22.27%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -43.32%, with the 5-day performance at 22.27% in the green. However, in the 30-day time frame, Apellis Pharmaceuticals Inc (NASDAQ:APLS) is 22.45% up. Looking at the short shares, we see there were 23.18 million shares sold at short interest cover period of 7.27 days.
The consensus price target for the stock as assigned by Wall Street analysts is 76, meaning bulls need an upside of 55.36% from its current market value. According to analyst projections, APLS’s forecast low is 39 with 113 as the target high. To hit the forecast high, the stock’s price needs a -233.04% plunge from its current level, while the stock would need to soar -14.94% for it to hit the projected low.
Apellis Pharmaceuticals Inc (APLS) estimates and forecasts
Data shows that the Apellis Pharmaceuticals Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -13.55% over the past 6 months, a 61.35% in annual growth rate that is considerably higher than the industry average of 17.70%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -13.70%. The 2024 estimates are for Apellis Pharmaceuticals Inc earnings to increase by 62.28%, but the outlook for the next 5-year period is at 33.30% per year.
APLS Dividends
Apellis Pharmaceuticals Inc is expected to release its next quarterly earnings report in January.
Apellis Pharmaceuticals Inc (NASDAQ:APLS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 13.98% of Apellis Pharmaceuticals Inc shares while 98.76% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 114.80%. There are 98.76% institutions holding the Apellis Pharmaceuticals Inc stock share, with WELLINGTON MANAGEMENT GROUP LLP the top institutional holder. As of 2024-06-30, the company held 13.2269% of the shares, roughly 16.39 million APLS shares worth $628.67 million.
ECOR1 CAPITAL, LLC holds the second largest percentage of outstanding shares, with 9.3681% or 11.61 million shares worth $445.26 million as of 2024-06-30.
